Professionals from the Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital actively participated in the 2026 Annual…
featured news home
Eva Muñoz-Couselo from VHIO has participated in two studies that reinforce the potential of oncolytic immunotherapies as a new therapeutic…
Results from the phase 3 TALAPRO-3 trial show that the combination of enzalutamide and talazoparib reduces the risk of progression…
The HERIZON-GEA-01 open-label, phase 3 clinical trial was designed to compare first-line treatment with the bispecific antibody zanidatamab plus chemotherapy…
Researchers at VHIO have published an article in the journal European Journal of Cancer on the evolution of targeted therapies…
Pharmaceutical company Gilead held the award ceremony for the 11th and 12th editions of the Gilead Biomedical Research Grants this…
International Clinical Trials Day is celebrated on May 20 to raise awareness about the fundamental role of biomedical research in…
After three years of collaboration, knowledge exchange, and joint efforts across Europe, the Comprehensive Cancer Infrastructures for Europe (CCI4EU) project has officially…
On April 28, Casa Milà – La Pedrera hosted the second session of the VHIOTalks 2026 series, titled “Innovation in…
The Hereditary Cancer Unit of the Medical Oncology Department at Vall d’Hebron University Hospital and the Hereditary Cancer Genetics Group…
